NCT06182696 - OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 26, 2023

Primary Completion Date

November 30, 2026

Study Completion Date

August 31, 2028

Conditions

Relapsed and/or Refractory Multiple Myeloma

Interventions

BIOLOGICAL

OriCAR-017

GPCRC5D-directed chimeric antigen receptor modified T cells

Trial Locations (5)

RECRUITING

The First Affiliated Hospital College of Medicine Zhejiang University, Hangzhou

NOT_YET_RECRUITING

Beijing GoBroad Hospital, Beijing

NOT_YET_RECRUITING

The First Affiliated Hospital with Nanjing Medical University, Nanjing

NOT_YET_RECRUITING

Tongji Hospital of Tongji University, Shanghai

RECRUITING

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan